The Company: Houdini Bio
Following the discovery of the Human Silencing Hub (HUSH) complex, Houdini Bio have developed an AI-enabled synthetic biology platform for redesigning complex gene constructs. They employ a proprietary “rulebook” capable of protecting the transgene from suppression in target cells. By preventing the loss of gene expression, their platform greatly increases the potency and durability of gene therapies, making them safer, cheaper and more efficacious.
The Challenge
Houdini Bio had demonstrated that its redesigned gene constructs could improve lentiviral vector (LV) expression in adherent cell systems. The critical next step was to demonstrate that this advantage could translate beyond an early proof of concept into a scalable, industry-relevant manufacturing setting, without compromising vector productivity, functional infectivity or product quality.
The Collaboration
CGT Catapult provided the manufacturing and analytical expertise needed to test Houdini Bio’s technology under progressively more industry-relevant conditions. Through Innovate UK’s CatapultRx ‘Start & Scale’ programme, the collaboration took a staged approach, progressing from small-scale evaluation to bioreactor scale-up and using robust analytical methods to assess both manufacturing performance and vector quality.
The work demonstrated that Houdini Bio’s redesigned gene constructs maintained its enhanced productivity and functional infectivity relative to unmodified controls as the process was translated towards scalable LV manufacturing. By combining Houdini Bio’s gene-design platform with CGT Catapult’s expertise in viral vector process development, scale-down and scale-up models, manufacturing and analytics, the collaboration generated an industry-relevant data package to support further process development, scale-up and commercial translation.
Where are they now?
The resulting data provide a credible, industry-relevant validation package to advance the technology to a higher Technology Readiness Level (TRL), reduce the risk of commercial adoption by third-party partners, and strengthen Houdini Bio’s fundraising efforts.
'Manufacturing is too often an afterthought in ATMP development, despite its implications for cost and viability. Working with CGT Catapult allowed us to demonstrate that our anti-HUSH lentiviruses improve transgene expression and durability whilst maintaining favourable manufacturability in industry-adopted, real-world production processes, baking in manufacturability from the outset.'
Dr Jonathan Cohen-Gold, Co-founder & CEO, Houdini Bio
*CatapultRx is a collaborative programme designed to accelerate the growth of high-potential companies in the medicines manufacturing sector. It is coordinated and delivered by the Centre for Process Innovation, Medicines Discovery Catapult, and Cell and Gene Therapy Catapult, on behalf of Innovate UK.